BRAF and cancer: The era of incurable ATC is gradually being replaced by molecular-based personalized therapies, which integrate multidisciplinary therapies including surgery, immunotherapy, radiation therapy, and targeted therapy.[17] In 2018, the FDA approved dabrafenib in combination with trametinib for the adjuvant treatment of patients with BRAF V600 mutation-positive ATC who could not be treated by resection or whose cancer cells had spread to other parts of the body.